5 results
Determination of possible Alzheimer pathology in the brain and to follow-up participants over time (by means of another research protocol). In addition, its [18F]-label with a half-life of 110 minutes will enable use in hospitals without an on-site…
We want to show in the current pilot trial that the current market ready automated device is safe and effective to use in humans as the proof of principle prototype, as well as check the instructions for use (IFU).
Objectives: The primary objectives of this study are: • Part 1 (dose-escalation): To evaluate the safety of SYD985 in combination with niraparib to determine the maximum tolerated dose (MTD) and recommended combination dose regimen for expansion (…
The main objective of the present study is to investigate the association between in vivo regional synaptic loss ([11C]UCB-J PET), in vivo regional tau pathology ([18F]flortaucipir PET) and in vivo regional Aβ pathology ([18F]florbetapir PET).…
We want to show in the current pilot trial that the current market ready automated device is safe and effective to use in humans as the proof of principle prototype, as well as check the instructions for use (IFU).